加拿大神经退行性衰老联盟影像工作组关于阿尔茨海默病疾病修饰治疗背景下影像检查的建议
加拿大神经退行性衰老联盟影像工作组采用德尔菲流程,召集放射学、神经病学、生物医学工程、核医学、MRI和医学物理专家,就阿尔茨海默病疾病修饰治疗中MRI和PET影像方案的标准化、扫描仪场强、基于风险特征的监测方案及最优方案时长达成共识,提出推荐意见。
要点
- 推荐跨制造商和扫描仪场强标准化采集影像协议,以确保临床治疗决策的一致性和可靠性。
- 推荐根据疾病修饰治疗的安全性和有效性特征制定量身定制的监测方案,且无论感知的治疗效果如何均应保持一致监测。
- 推荐在1.5T或3T扫描仪上进行MRI筛查并采用适配方案,认为20-30分钟的最优方案时长可行。
核心结论
- 该指南旨在提高影像数据质量和一致性,促进更好的临床决策并改善患者结局;需要进一步研究以完善这些方案并应对新疾病修饰治疗带来的不断变化的挑战;认识到提供额外MRI和PET扫描的行政、财务和后勤能力需要仔细规划。
研究设计与样本
- 加拿大神经退行性衰老联盟影像工作组采用德尔菲流程制定建议,从放射学、神经病学、生物医学工程、核医学、MRI和医学物理领域招募专家,通过调查和会议就关键问题达成共识,草案建议经多轮迭代和专家讨论完善。
诊断标准与关键数值
- 推荐跨制造商和扫描仪场强标准化采集影像协议,以确保临床治疗决策的一致性和可靠性。
- 推荐根据疾病修饰治疗的安全性和有效性特征制定量身定制的监测方案。
- 推荐无论感知的治疗效果如何均保持一致监测。
- 推荐在1.5T或3T扫描仪上进行MRI筛查并采用适配方案。
- 认为20-30分钟的最优方案时长可行,并建议了具体序列。
临床应用与阅片要点
- 制定影像协议时应跨制造商和扫描仪场强进行标准化,以保证临床治疗决策的一致性和可靠性。
- 监测方案应根据疾病修饰治疗的安全性和有效性特征进行量身定制。
- 无论感知的治疗效果如何,均应保持一致监测。
- MRI筛查应在1.5T或3T扫描仪上进行并采用适配方案,20-30分钟的方案时长被认为是可行的。
局限性
- 需要进一步研究以完善这些方案并应对新疾病修饰治疗带来的不断变化的挑战。
- 认识到提供额外MRI和PET扫描的行政、财务和后勤能力需要仔细规划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Disease-modifying therapies (DMTs) for Alzheimer's disease (AD) are emerging following successful clinical trials of therapies targeting amyloid beta (Aβ) protofibrils or plaques. Determining patient eligibility and monitoring treatment efficacy and adverse events, such as Aβ-related imaging abnormalities, necessitates imaging with MRI and PET. The Canadian Consortium on Neurodegeneration in Aging (CCNA) Imaging Workgroup aimed to synthesize evidence and provide recommendations on implementing imaging protocols for AD DMTs in Canada.
METHODS: The workgroup employed a Delphi process to develop these recommendations. Experts from radiology, neurology, biomedical engineering, nuclear medicine, MRI and medical physics were recruited. Surveys and meetings were conducted to achieve consensus on key issues, including protocol standardization, scanner strength, monitoring protocols based on risk profiles and optimal protocol lengths. Draft recommendations were refined through multiple iterations and expert discussions.
RESULTS: The recommendations emphasize standardized acquisition imaging protocols across manufacturers and scanner strengths to ensure consistency and reliability of clinical treatment decisions, tailored monitoring protocols based on DMTs' safety and efficacy profiles, consistent monitoring regardless of perceived treatment efficacy and MRI screening on 1.5T or 3T scanners with adapted protocols. An optimal protocol length of 20-30 minutes was deemed feasible; specific sequences are suggested.
CONCLUSION: The guidelines aim to enhance imaging data quality and consistency, facilitating better clinical decision-making and improving patient outcomes. Further research is needed to refine these protocols and address evolving challenges with new DMTs. It is recognized that administrative, financial and logistical capacity to deliver additional MRI and positron emission tomography scans require careful planning.
引用
- Duchesne S, Collins DL, Barlow L, et al. Recommendations on Imaging in the Context of Alzheimer's Disease-Modifying Therapies from the CCNA Imaging Workgroup. Can J Neurol Sci. 2024. PMID: 39494933. doi:10.1017/cjn.2024.338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。